A Phase 3 interventional study of Momelotinib and Placebo to match momelotinib in Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Sierra Oncology LLC - a GSK company. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-29.
Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
There will be two phases to this study. The lead-in phase will evaluate the safety, pharmacokinetics, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with nab-paclitaxel and gemcitabine (nab-P + G) in adults with previously untreated metastatic pancreatic ductal adenocarcinoma. The randomized treatment phase will evaluate the efficacy, safety, and tolerability of nab-P + G with either MMB administered at the MTD or placebo in adults with previously untreated metastatic pancreatic ductal adenocarcinoma. Participants will continue study treatment until disease progression, unacceptable toxicity, consent withdrawal, or participant's refusal of treatment. Following treatment, participants will be followed for safety for 30 days and for survival approximately every 3 months for up to 3 years.
Sierra Oncology LLC - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
First submitted before Sierra Oncology LLC became part of GlaxoSmithKline.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Presence of pancreatic adenocarcinoma plus 1 of the following:
Pathologist confirmed histological/cytological diagnosis of adenocarcinoma consistent with pancreas origin in conjunction with either:
Adequate organ function defined as follows:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive momelotinib plus nab-paclitaxel and gemcitabine.
Drug: Momelotinib · Drug: Nab-paclitaxel · Drug: Gemcitabine
Participants will receive placebo to match momelotinib plus nab-paclitaxel and gemcitabine.
Drug: Placebo to match momelotinib · Drug: Nab-paclitaxel · Drug: Gemcitabine
Tablet (s) administered orally once or twice daily
Also known as: GS-0387, CYT387
Placebo to match momelotinib tablets administered orally once or twice daily
Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events
Dose limiting toxicities were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Dose limiting toxicities referred to toxicities experienced during the first 28 days (Cycle 1) of treatment that were judged to be clinically significant and related to study treatment. No statistical analysis was planned or performed for this endpoint.
Time frame: Up to 28 Days
Randomized Treatment Phase: Overall Survival (OS)
Overall survival was defined as the time interval from first dose date of MMB to death from any cause
Time frame: Baseline up to the Date of Death or Censoring, up to 3 years
Lead-In Phase: Overall Survival (OS)
Overall survival was defined as the time interval from first dose date of MMB to death from any cause
Time frame: Baseline up to the Date of Death or Censoring, up to 3 years
Lead-In Phase: Progression-Free Survival (PFS)
Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression is progression based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria v1.1. Data from survival, non-progressing participants will be censored at the earliest of the time of initiation of anti-tumor therapy other than the study treatment or the last time that lack of definitive disease progression was objectively documented while on study.
Time frame: Baseline up to the Date of Event or Censoring, up to 3 years
Lead-In Phase: Overall Response Rate (ORR)
The ORR was defined as the proportion of participants who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR) as assessed by RECIST v1.1.
Time frame: Baseline up to the Last Tumor Assessment Date, up to 3 years
Randomized Treatment Phase: Progression-Free Survival (PFS)
Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause
Time frame: Baseline up to the Date of Event or Censoring, up to 3 years
Randomized Treatment Phase: Overall Response Rate
The ORR was defined as the proportion of subjects who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR)
Time frame: Baseline up to the Last Tumor Assessment Date, up to 3 years
Participants were enrolled at study sites in the United States (US). The first participant was screened on 02 June 2014. The last study visit occurred on 10 April 2017.
| Milestone | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 |
|---|---|---|---|---|---|
| Started | 7 | 4 | 7 | 3 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 4 | 7 | 3 | 4 |
| Withdrew: Death | 4 | 3 | 6 | 0 | 3 |
| Withdrew: Withdrew consent from study | 1 | 1 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 0 | 1 | 1 | 1 |
Dose limiting toxicities were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Dose limiting toxicities referred to toxicities experienced during the first 28 days (Cycle 1) of treatment that were judged to be clinically significant and related to study treatment. No statistical analysis was planned or performed for this endpoint.
| percentage of participants | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 |
|---|---|---|---|---|---|
| Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events | 16.7 | 0 | 16.7 | 0 | 0 |
Overall survival was defined as the time interval from first dose date of MMB to death from any cause
No measurements were reported for this outcome.
Overall survival was defined as the time interval from first dose date of MMB to death from any cause
| Months | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 |
|---|---|---|---|---|---|
| Lead-In Phase: Overall Survival (OS) | 12.4 (3.9 to 22.2) | 5.1 (3.7 to 11.3) | 8.7 (7.3 to 18.3) | 5.6 (4.8 to 18.1) | 7.1 (5.9 to 12.0) |
Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression is progression based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria v1.1. Data from survival, non-progressing participants will be censored at the earliest of the time of initiation of anti-tumor therapy other than the study treatment or the last time that lack of definitive disease progression was objectively documented while on study.
| Months | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 |
|---|---|---|---|---|---|
| Lead-In Phase: Progression-Free Survival (PFS) | 5.3 (1.4 to 7.4) | 3.2 (1.9 to 4.8) | 5.5 (5.3 to 7.2) | 5.3 (0.0 to 13.0) | 5.5 (4.5 to 10.1) |
The ORR was defined as the proportion of participants who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR) as assessed by RECIST v1.1.
| Participants | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 |
|---|---|---|---|---|---|
| Complete Response (CR) | 2 | 1 | 3 | 1 | 0 |
| Partial Response (PR) | 2 | 2 | 4 | 1 | 4 |
Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause
No measurements were reported for this outcome.
The ORR was defined as the proportion of subjects who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR)
No measurements were reported for this outcome.
Collected over Baseline up to the last dose date plus 30 days (maximum exposure= 63.7 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MMB Dose Level 1 | 4/7 (57.1%) | 4/7 (57.1%) | 7/7 (100%) |
| MMB Dose Level 2 | 3/4 (75%) | 3/7 (42.9%) | 4/4 (100%) |
| MMB Dose Level 3 | 6/7 (85.7%) | 5/7 (71.4%) | 7/7 (100%) |
| MMB Dose Level 4 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| MMB Dose Level 5 | 3/4 (75%) | 4/4 (100%) | 4/4 (100%) |
| Event | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/7 | 0/7 | 3/7 | 0/3 | 1/4 |
| NeutropeniaBlood and lymphatic system disorders | 0/7 | 0/7 | 1/7 | 1/3 | 0/4 |
| HaematemesisGastrointestinal disorders | 0/7 | 0/7 | 0/7 | 1/3 | 0/4 |
| PyrexiaGeneral disorders | 1/7 | 0/7 | 1/7 | 1/3 | 1/4 |
| PolyneuropathyNervous system disorders | 0/7 | 0/7 | 0/7 | 1/3 | 0/4 |
| SepsisInfections and infestations | 0/7 | 0/7 | 2/7 | 0/3 | 0/4 |
| Chest painGeneral disorders | 0/7 | 0/7 | 0/7 | 0/3 | 1/4 |
| Generalised oedemaGeneral disorders | 0/7 | 0/7 | 0/7 | 0/3 | 1/4 |
| Mucosal inflammationGeneral disorders | 0/7 | 0/7 | 0/7 | 0/3 | 1/4 |
| Bile duct obstructionHepatobiliary disorders | 0/7 | 0/7 | 0/7 | 0/3 | 1/4 |
| Event | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/7 | 3/4 | 3/7 | 3/3 | 3/4 |
| NauseaGastrointestinal disorders | 5/7 | 4/4 | 4/7 | 3/3 | 3/4 |
| FatigueGeneral disorders | 5/7 | 3/4 | 6/7 | 2/3 | 4/4 |
| AnaemiaBlood and lymphatic system disorders | 6/7 | 2/4 | 4/7 | 2/3 | 3/4 |
| NeutropeniaBlood and lymphatic system disorders | 0/7 | 1/4 | 1/7 | 2/3 | 3/4 |
| Abdominal painGastrointestinal disorders | 2/7 | 1/4 | 3/7 | 1/3 | 3/4 |
| ConstipationGastrointestinal disorders | 2/7 | 3/4 | 3/7 | 2/3 | 3/4 |
| VomitingGastrointestinal disorders | 3/7 | 3/4 | 4/7 | 0/3 | 3/4 |
| Oedema peripheralGeneral disorders | 4/7 | 1/4 | 2/7 | 2/3 | 3/4 |
| PyrexiaGeneral disorders | 3/7 | 2/4 | 3/7 | 1/3 | 3/4 |
All Enrolled Analysis Set: all participants who received a study participant identification number in the study after screening.
| Age, Continuous(years) | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 | Total |
|---|---|---|---|---|---|---|
| Mean | 59.9 ± 12.32 | 63.5 ± 12.12 | 64.7 ± 8.79 | 52.0 ± 5.00 | 59.0 ± 9.13 | 60.7 ± 10.21 |
| Sex: Female, Male(Participants) | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 3 | 2 | 0 | 1 | 8 |
| Male | 5 | 1 | 5 | 3 | 3 | 17 |
| Race/Ethnicity, Customized(Participants) | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 | Total |
|---|---|---|---|---|---|---|
| Asian | 0 | 0 | 1 | 0 | 0 | 1 |
| White | 6 | 3 | 6 | 3 | 4 | 22 |
| Other | 1 | 1 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 6 | 4 | 7 | 3 | 4 | 24 |
| Region of Enrollment(Participants) | MMB Dose Level 1 | MMB Dose Level 2 | MMB Dose Level 3 | MMB Dose Level 4 | MMB Dose Level 5 | Total |
|---|---|---|---|---|---|---|
| United States | 7 | 4 | 7 | 3 | 4 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2014 to primary completion in Apr 2017, 34 months.
Results were first posted in May 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Momelotinib
Sierra Oncology LLC - a GSK company →